2023
Efficacy and Safety of Hyperbaric Oxygen Therapy in Fistulizing Crohn’s Disease
Dokmak A, Sweigart B, Orekondy N, Jangi S, Weinstock J, Hamdeh S, Kochar G, Shen B, Levy A. Efficacy and Safety of Hyperbaric Oxygen Therapy in Fistulizing Crohn’s Disease. Journal Of Clinical Gastroenterology 2023, 58: 120-130. PMID: 37682003, DOI: 10.1097/mcg.0000000000001905.Peer-Reviewed Original ResearchConceptsHyperbaric oxygen therapySystematic reviewSafety of hyperbaric oxygen therapyHyperbaric oxygen therapy sessionsFistulizing Crohn's diseaseClinical responseCochrane Handbook guidelinesRisk of biasCrohn's diseaseFistulizing CDRandomized controlled trialsWeb of ScienceOxygen therapyStudy biasMeta-analysesCochrane Library databasesMeta-regressionEffective treatment optionBenefits of hyperbaric oxygen therapyControlled trialsRegulate inflammatory pathwaysMeta-analysisInflammatory bowel diseaseIncreased tissue oxygen levelsFistula typePredictors and Etiologies of Clinical Relapse Among Patients With Ulcerative Colitis in Deep Remission
Zeina T, Gandhi S, Mittal A, Levy A, Weinstock J, Singh S, Jangi S. Predictors and Etiologies of Clinical Relapse Among Patients With Ulcerative Colitis in Deep Remission. Journal Of Clinical Gastroenterology 2023, 58: 195-199. PMID: 36753459, PMCID: PMC10406966, DOI: 10.1097/mcg.0000000000001834.Peer-Reviewed Original ResearchConceptsEtiology of relapseRisk of relapseCumulative risk of relapseRisk of clinical relapseDeep remissionDiscontinuation of therapyClinical relapseUlcerative colitisNormalization of C-reactive proteinCumulative riskRetrospective cohort studyC-reactive proteinTufts Medical CenterEndoscopic remissionHistological remissionRelapse riskIdentified etiologyRemissionRelapseCohort studyPatientsHistological changesMedical recordsColitisElectronic medical records
2022
Adjunctive Hyperbaric Oxygen Therapy for High Risk Peristomal Pyoderma Gangrenosum
Zeina T, Levy A. Adjunctive Hyperbaric Oxygen Therapy for High Risk Peristomal Pyoderma Gangrenosum. Digestive Diseases And Sciences 2022, 67: 4597-4598. PMID: 35989384, DOI: 10.1007/s10620-022-07646-x.Peer-Reviewed Original ResearchNatural History of New-onset Inflammatory Bowel Disease Among Patients With Multiple Sclerosis
Gandhi S, Zelman S, De Armas R, Hemond C, Levy A, Singh S, Korzenik J, Jangi S. Natural History of New-onset Inflammatory Bowel Disease Among Patients With Multiple Sclerosis. Inflammatory Bowel Diseases 2022, 28: 1614-1617. PMID: 35348692, PMCID: PMC9527605, DOI: 10.1093/ibd/izac053.Peer-Reviewed Original Research